"ctDNA as a minimal residual disease biomarker after curative-intent pancreatic cancer resection" OR "ctDNA as a prognostic biomarker after curative-intent pancreatic cancer resection — systematic review and meta-analysis" would you recommend the below to be a good meta-analysis focused topic with good impact and feasibility
Searching PubMed
ctDNA minimal residual disease pancreatic cancer resection
Searching PubMed
circulating tumor DNA pancreatic cancer surgery prognosis recurrence
Searching the Web
ctDNA MRD pancreatic cancer resection systematic review meta-analysis 2024 2025
Reading Article
Searching PubMed
ctDNA postoperative pancreatic ductal adenocarcinoma recurrence survival
Reading Web Page
ctDNA MRD pancreatic cancer resection post-operative studies cohort size outcomes
I now have enough data to give you a thorough, evidence-grounded assessment. Here is my full analysis:
Assessment: ctDNA as MRD/Prognostic Biomarker After Curative-Intent PDAC Resection — Meta-Analysis Feasibility & Impact
The Short Answer
Conditionally yes - but with an important caveat: A focused, well-scoped meta-analysis on this topic is publishable and impactful, but a directly comparable meta-analysis already exists (2023). To proceed, you need to either update/expand that prior work or differentiate your scope meaningfully. Here is the full breakdown.
1. The Existing Meta-Analysis — What Already Exists
The most directly relevant prior work is:
Alqahtani A, et al. "Prognostic utility of preoperative and postoperative KRAS-mutated ctDNA in resected PDAC." Surg Oncol. 2023 Dec. [PMID: 37852124]
Key details:
- 15 studies, 868 patients
- Postoperative ctDNA+: RFS HR 3.32 (95% CI 2.19-5.03); OS HR 6.62 (95% CI 2.18-20.16)
- Preoperative ctDNA+: RFS HR 2.07; OS HR 2.17
- Limitation: KRAS-only detection methods, mostly tumor-agnostic approaches
This means a simple replication is not viable. However, the field has moved fast enough - and this 2023 paper has real gaps - that an updated or more refined meta-analysis is very justified.
2. Gaps That Justify a New Meta-Analysis
Several meaningful gaps exist that a new study could fill:
| Gap in Alqahtani 2023 | Your Opportunity |
|---|---|
| KRAS-only ctDNA detection | Include tumor-informed (personalized) NGS panels - Signatera, FoundationOne Tracker, etc. |
| Only 868 patients / 15 studies | Multiple new cohorts published 2023-2026 (Aaquist 2026, Zhang 2025, Maulat 2024, Watanabe 2022, Wang 2023, etc.) |
| No subgroup by detection platform | Stratify: tumor-informed vs. tumor-agnostic; ddPCR vs. NGS |
| No lead-time data pooled | Median ctDNA-to-imaging lead time can now be pooled (3.6-6.5 months across recent studies) |
| No MRD clearance analysis | ctDNA clearance during adjuvant therapy as a separate endpoint |
| No neoadjuvant subgroup | Studies including borderline-resectable/neoadjuvant-treated patients are now available |
3. Clinical Impact Score: HIGH
This topic scores well on all the dimensions that drive journal interest:
- Disease burden: PDAC is among the highest-mortality GI cancers. 5-year survival after resection remains ~25-30%. Recurrence prediction has direct clinical utility.
- Clinical actionability: Positive post-op ctDNA could select patients for intensified adjuvant therapy or clinical trial enrollment. NCT06966440 ("Adjuvant Pancreatic Therapy Guided by MRD") is already running - your meta-analysis would directly inform that trial's biological rationale.
- Theranostic relevance: ctDNA clearance during adjuvant chemotherapy as a treatment-response biomarker is a natural extension.
- Timeliness: The 2025-2026 literature (Aaquist, Wang, Zhang, Safiejko, Feng) has substantially expanded the evidence base since the 2023 meta-analysis.
Target journals: Annals of Surgical Oncology, HPB, EJSO, Pancreatology, JCO Precision Oncology, Gut (if very high quality).
4. Feasibility Assessment
| Factor | Verdict |
|---|---|
| Number of eligible studies | ~15-25 new/updated cohorts (2022-2026) on top of the prior meta-analysis base |
| Sample sizes | Small-moderate (most n=20-113); aggregate likely reaches ~1,000-1,500 patients after update |
| Outcome homogeneity | Good - RFS/DFS and OS are consistently reported; HR with 95% CI available in most |
| Heterogeneity risk | Moderate-high - detection platforms vary (ddPCR, BEAMing, NGS tumor-informed); timing of sampling differs |
| PROSPERO registration | Feasible and recommended; no competing registered protocol found |
| Data extraction | HR and CI extractable from KM curves via Parmar/Tierney methods where not directly reported |
Main feasibility challenge: Small individual cohort sizes mean confidence intervals remain wide in some subgroups. Plan for a sensitivity analysis by platform type and sampling time point.
5. Suggested Refined Scope (to differentiate from Alqahtani 2023)
Two strong angles are available:
Option A — Updated comprehensive meta-analysis with platform stratification:
- PICO: Adults with resected PDAC | post-resection ctDNA status (any platform) | RFS, OS, lead time | no ctDNA / ctDNA-negative
- Subgroups: tumor-informed NGS vs. KRAS-only; early post-op (<30 days) vs. surveillance; neoadjuvant-treated vs. upfront surgery
- Adds meaningful new data and addresses the platform-agnosticism limitation of 2023 paper
Option B — Narrower MRD-specific angle (stronger clinical focus):
- Restrict to postoperative ctDNA only (not preoperative)
- Add MRD clearance during adjuvant therapy as a distinct endpoint
- Frame around clinical decision-support: can post-op ctDNA guide adjuvant therapy intensification?
- This is the more novel and clinically impactful framing - less overlap with 2023 paper
Option B is arguably more publishable in 2026 because it directly addresses the therapeutic question that NCT06966440 and similar trials are trying to answer.
6. Potential Pitfalls to Plan Around
- Detection sensitivity varies dramatically by tumor-informed vs. KRAS-only approach. Pooling them may produce noise. Pre-specify subgroup analyses.
- Sampling time heterogeneity: "Post-op" ranges from 7 days to 3 months across studies - this needs to be handled in inclusion criteria or as a moderator.
- Publication bias: Small positive studies are likely over-represented; plan a funnel plot + Egger's test.
- KRAS wild-type PDAC (~10% of cases) is excluded from KRAS-only ctDNA studies - note this limitation.
- The Yanala/Dickey abstract from ASCO 2024 (JCO Suppl) describes a single-institution series + meta-analysis on exactly this topic, so check whether a full peer-reviewed version has been published yet. If it has, review the scope carefully.
7. Final Recommendation
Recommended: Yes, proceed - but with Option B framing.
Frame it specifically as: "Postoperative ctDNA as a minimal residual disease biomarker in resected PDAC: prognostic accuracy, lead time over imaging, and implications for adjuvant therapy - a systematic review and meta-analysis."
This framing:
- Differs from the 2023 KRAS-focused paper in scope and clinical question
- Captures the 2023-2026 wave of tumor-informed studies not included in the prior work
- Is directly clinically relevant to the MRD-guided treatment trials now enrolling
- Has sufficient primary studies (~15-20) to support a robust pooled analysis
Register on PROSPERO before starting data extraction. The evidence base is mature enough for a publishable meta-analysis, and the clinical question is genuinely open.
Can you simplify this answer and make it a bit more understanding
Here's a simplified version:
Is This a Good Meta-Analysis Topic? — Plain Answer
What the topic is asking
After surgeons remove a pancreatic cancer, some patients still have tiny amounts of cancer left in their body that scans can't detect yet. This is called minimal residual disease (MRD). A blood test called ctDNA (circulating tumor DNA) can detect tiny fragments of cancer DNA in the bloodstream — potentially catching this hidden disease weeks or months before it shows up on a CT scan.
Your proposed meta-analysis would pool all existing studies to ask: "Does a positive ctDNA test after pancreatic cancer surgery reliably predict who will relapse and who won't?"
Is the topic impactful? YES
- Pancreatic cancer has one of the worst survival rates of any cancer. Even after successful surgery, most patients relapse.
- If ctDNA can flag high-risk patients early, doctors could intensify treatment for those patients — or spare low-risk patients from unnecessary chemotherapy toxicity.
- There is already a clinical trial (NCT06966440) enrolling patients based on exactly this concept. Your meta-analysis would directly support or inform that trial.
Is it feasible? YES, but needs careful scoping
There are enough studies (roughly 15-25 cohorts, ~1,000+ patients total when pooled) to do a meaningful analysis. The outcomes — recurrence-free survival and overall survival — are consistently reported across studies, which makes pooling possible.
The main challenge is that different studies used different detection methods (some only looked for KRAS mutations, others used personalized full-genome panels). You'll need to account for this in your analysis.
One important thing to know first
A similar meta-analysis was already published in 2023 (Alqahtani et al., Surgical Oncology). It included 15 studies and 868 patients and found that a positive post-surgery ctDNA test was strongly linked to worse survival.
This means you can't just repeat the same analysis - you need to add something new.
What makes your version worth doing anyway
The 2023 paper has real gaps you can improve on:
- It only used old KRAS-based tests. Newer "tumor-informed" personalized ctDNA tests (more accurate) have been validated in multiple studies since then - none included in that paper.
- The field has grown. Several new studies were published in 2024-2026 that weren't available in 2023.
- No one has pooled the lead-time data - i.e., how many weeks/months earlier does ctDNA detect relapse compared to a CT scan?
- No one has focused on ctDNA clearance - does a positive ctDNA test that turns negative during chemotherapy mean the treatment is working?
Best angle to take
Focus your meta-analysis on postoperative ctDNA only (not before surgery), with a specific clinical question: Can post-op ctDNA guide adjuvant treatment decisions?
This is more novel, more clinically useful, and less overlap with the existing 2023 paper.
Bottom line
| Impact | High - directly relevant to one of the deadliest cancers |
| Feasibility | Moderate-High - enough studies exist, data is extractable |
| Novelty | Good, if you focus on newer tumor-informed tests and the treatment-guidance angle |
| Risk | Another group (Yanala/Dickey, ASCO 2024) may publish a full paper soon - act quickly and register on PROSPERO first |
Go ahead with it - just register your protocol on PROSPERO before starting, and frame it around the newer personalized ctDNA tests and the treatment decision-making question.
This is a shared conversation. Sign in to Orris to start your own chat.